Area of research
Radiology, Nuclear Medicine and Imaging · Neurology
Research interest
Research interests include Medical Imaging Techniques and Applications, Radiopharmaceutical Chemistry and Applications, Neuroblastoma Research and Treatments, and PARP inhibition in cancer therapy.
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
The Lancet Oncology Commission: Radiotherapy & Theranostic Services in LMICs: Minding & Mending the Gaps
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology.
Cancer Informatics for Cancer Centers: Sharing Ideas on How to Build an Artificial Intelligence-Ready Informatics Ecosystem for Radiation Oncology.
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
The potential of a medium-cost long axial FOV PET system for nuclear medicine departments
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy
NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
A Review of Contemporary Data on Surgically Resected Renal Masses—Benign or Malignant?